MTOR and non-small cell lung carcinoma: A growing body of evidences indicate that excessive activation of AKT/mTOR and COX-2/PGE2 signal pathways as a common occurrence in human cancers [46, 47], furthermore, inhibitors specific to these pathways has been showed certain antitumor activities, including tumor regressions and prolonged stable disease, which has been reported among patients with a variety of malignancies, including non-small cell lung cancers [48-52].